{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:44:15Z","timestamp":1790801055927,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.eclinm.2021.100981","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:20:35Z","timestamp":1624753235000},"page":"100981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Nitazoxanide superiority to placebo to treat moderate COVID-19 \u2013 A Pilot prove of concept randomized double-blind clinical trial."],"prefix":"10.1016","volume":"37","author":[{"given":"Vinicius Fontanesi","family":"Blum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Cimerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Tierno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acioly","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentino","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Cristina","family":"Bellei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Maricato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Vassao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-600X","authenticated-orcid":false,"given":"Danilo","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3413-005X","authenticated-orcid":false,"given":"Juliana","family":"Galinskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M\u00e1rio Ramos","family":"Janini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Reis","family":"Santos-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-2447","authenticated-orcid":false,"given":"Alda Maria","family":"Da-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Sobhie","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2021.100981_bib0001","doi-asserted-by":"crossref","unstructured":"Valencia D.N. Brief Review on COVID-19: the 2020 pandemic caused by SARS-CoV-2. Cureus. 2020; 12. doi:10.7759\/cureus.7386.","DOI":"10.7759\/cureus.7386"},{"key":"10.1016\/j.eclinm.2021.100981_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01028-2020","article-title":"Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers","volume":"55","author":"Rello","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eclinm.2021.100981_bib0003","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.100981_bib0004","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.eclinm.2021.100981_bib0005","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1152\/physrev.00020.2020","article-title":"SARS-CoV-2 and COVID-19: from the bench to the bedside","volume":"100","author":"Romagnoli","year":"2020","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.eclinm.2021.100981_bib0006","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.eclinm.2021.100981_bib0007","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine Storm in COVID-19: the current evidence and treatment strategies","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm\u201d in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"Journal of Infect"},{"key":"10.1016\/j.eclinm.2021.100981_bib0009","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.eclinm.2021.100981_bib0010","first-page":"1","article-title":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study","volume":"369","author":"Zheng","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2021.100981_bib0011","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1164\/rccm.202003-0572LE","article-title":"SARS-CoV-2 viral load in clinical samples from critically ill patients","volume":"201","author":"Huang","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eclinm.2021.100981_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1008737","article-title":"Interplay between SARS-CoV-2 and the type I interferon response","volume":"16","author":"Ribero","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.eclinm.2021.100981_bib0013","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14740\/jmc3520","article-title":"Macrophage activation in COVID-19 patients in intensive care unit","volume":"11","author":"Labro","year":"2020","journal-title":"J Med Cases"},{"key":"10.1016\/j.eclinm.2021.100981_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0317-2","article-title":"Macrophages: a Trojan horse in COVID-19?","volume":"20","author":"Park","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118102","article-title":"Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions","volume":"257","author":"Jafarzadeh","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.eclinm.2021.100981_bib0016","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2021.100981_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2020.05.009","article-title":"IL-6: relevance for immunopathology of SARS-CoV-2","volume":"53","author":"Gubernatorova","year":"2020","journal-title":"Cytokine Growth Fact Rev"},{"key":"10.1016\/j.eclinm.2021.100981_bib0018","first-page":"1","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"371","author":"Cevik","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2021.100981_bib0019","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jmv.20556","article-title":"Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections","volume":"78","author":"Okabayashi","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2020.01441","article-title":"Immune Response, Inflammation, and the Clinical Spectrum of COVID-19","volume":"11","author":"Garc\u00eda","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0021","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.eclinm.2021.100981_bib0022","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2021.100981_bib0023","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eclinm.2021.100981_bib0024","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.eclinm.2021.100981_bib0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.virol.2018.03.023","article-title":"Inhibition of vaccinia virus replication by Nitazoxanide","volume":"518","author":"Hickson","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.eclinm.2021.100981_bib0026","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eclinm.2021.100981_bib0027","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3389\/fimmu.2019.00531","article-title":"Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy","volume":"10","author":"Pizzorno","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0028","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of Nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2021.100981_bib0029","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","article-title":"Synergistic and antagonistic drug combinations against SARS-CoV-2","volume":"29","author":"Bobrowski","year":"2021","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.eclinm.2021.100981_bib0030","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of Anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human Pharmacokinetics","volume":"108","author":"Arshad","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2021.100981_bib0031","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5414\/CPP40221","article-title":"Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5g and 1g b.i.d","volume":"40","author":"Stockis","year":"2002","journal-title":"CP"},{"key":"10.1016\/j.eclinm.2021.100981_bib0032","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2055-6640(20)30017-0","article-title":"Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19","volume":"6","author":"Pepperrell","year":"2020","journal-title":"Journal of Virus Eradication"},{"key":"10.1016\/j.eclinm.2021.100981_bib0033","unstructured":"World Health Organization. 2020 COVID-19 therapeutic trial synopsis. https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf"},{"key":"10.1016\/j.eclinm.2021.100981_bib0034","unstructured":"Helios M., Rosario D. Package PWR title basic functions for power analysis. 2020."},{"key":"10.1016\/j.eclinm.2021.100981_bib0035","unstructured":"R: a language and environment for statistical computing. 2020 Available from: https:\/\/www.gbif.org\/pt\/tool\/81287\/r-a-language-and-environment-for-statistical-computing"},{"key":"10.1016\/j.eclinm.2021.100981_bib0036","first-page":"59","article-title":"Thalidomide is associated with increased T cell activation and inflammation in Antiretroviral-naive HIV-infected individuals in a randomised clinical trial of efficacy and safety","volume":"23","author":"Vergara","year":"2017","journal-title":"E Bio Med"},{"key":"10.1016\/j.eclinm.2021.100981_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173748","article-title":"A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19","volume":"891","author":"Lokhande","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0038","article-title":"Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis","volume":"15","author":"Rajoli","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2021.100981_bib0040","article-title":"Plasma CRP level is positively associated with the severity of COVID-19","volume":"15","author":"Chen","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.eclinm.2021.100981_bib0041","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intens Care Med"},{"key":"10.1016\/j.eclinm.2021.100981_bib0042","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.eclinm.2021.100981_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118167","article-title":"The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"258","author":"Akbari","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.eclinm.2021.100981_bib0044","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2021.100981_bib0045","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2021.100981_bib0046","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI114265","article-title":"Neutrophil-activating peptide-1\/interleukin 8, a novel cytokine that activates neutrophils","volume":"84","author":"Baggiolini","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eclinm.2021.100981_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241659","article-title":"Lymphopenia predicted illness severity and recovery in patients with COVID-19: a single-center, retrospective study","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eclinm.2021.100981_bib0048","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/JLB.4HI0720-470R","article-title":"Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes","volume":"109","author":"Zhang","year":"2021","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.eclinm.2021.100981_bib0049","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","article-title":"Coronavirus RNA proofreading: molecular basis and therapeutic targeting","volume":"79","author":"Robson","year":"2020","journal-title":"Molecular Cell"},{"key":"10.1016\/j.eclinm.2021.100981_bib0050","article-title":"COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1","author":"Naveca","year":"2021","journal-title":"Review"},{"key":"10.1016\/j.eclinm.2021.100981_bib0051","article-title":"Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial","author":"Rocco","year":"2020","journal-title":"Eur Respir J"}],"updated-by":[{"DOI":"10.1016\/j.eclinm.2021.101203","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021002613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021002613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:07:50Z","timestamp":1762888070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021002613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":51,"alternative-id":["S2589537021002613"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100981","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitazoxanide superiority to placebo to treat moderate COVID-19 \u2013 A Pilot prove of concept randomized double-blind clinical trial.","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100981"}}